|
C6ORF120 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.66155977865401E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.73059999664105E-09 |
| Normal-vs-Stage2 |
9.0120999551857E-10 |
| Normal-vs-Stage3 |
4.44089209850063E-16 |
| Normal-vs-Stage4 |
1.72362124573056E-12 |
| Stage1-vs-Stage2 |
2.721400E-01 |
| Stage1-vs-Stage3 |
7.883000E-03 |
| Stage1-vs-Stage4 |
1.838080E-03 |
| Stage2-vs-Stage3 |
3.304600E-01 |
| Stage2-vs-Stage4 |
1.077820E-01 |
| Stage3-vs-Stage4 |
4.181000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
1.958820E-04 |
| Normal-vs-Asian |
3.03869995832429E-09 |
| Caucasian-vs-AfricanAmerican |
1.813850E-01 |
| Caucasian-vs-Asian |
6.383800E-01 |
| AfricanAmerican-vs-Asian |
3.469000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.72004641033163E-14 |
| Normal-vs-Female |
4.89575047168955E-12 |
| Male-vs-Female |
2.760800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.35539999621426E-08 |
| Normal-vs-Age(41-60Yrs) |
8.26005930321116E-14 |
| Normal-vs-Age(61-80Yrs) |
1.6885381981524E-12 |
| Normal-vs-Age(81-100Yrs) |
4.41469999999944E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.604790E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.031700E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.139200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.692000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.020800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.612600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.938300E-03 |
| Classical-VS-Follicular |
6.782000E-01 |
| Classical-VS-Other |
5.386600E-01 |
| Classical-VS-Normal |
1.64468438867971E-12 |
| Tall-VS-Follicular |
2.406200E-02 |
| Tall-VS-Other |
5.502400E-01 |
| Tall-VS-Normal |
5.31685806492987E-13 |
| Follicular-VS-Other |
6.087000E-01 |
| Follicular-VS-Normal |
1.27809999994621E-06 |
| Other-VS-Normal |
1.298710E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.4170890823334E-14 |
| Normal-vs-N1 |
1.94433358302604E-12 |
| N0-vs-N1 |
8.102000E-02 |
|
|
